Carla Cox, PhD, registered dietician and certified diabetes educator, discusses key information about COVID-19 that individuals with diabetes should know.
Ixekizumab (Taltz, Eli Lilly) is the first interleukin-17A antagonist to be approved for non-radiographic axial spondyloarthritis.
Bristol Myers Squibb announced the commercial US launch of ozanimod (Zeposia) for the treatment of relapsing forms of multiple sclerosis.
Impax requested that pharmacists who have dispensed Impax’s epinephrine injection, USP auto-injector 0.3 mg since December 20, 2018 contact all patients who received the device and provide instructions for inspection.
The study’s authors examined the opportunity to decrease the overall cost of bortezomib by $300-400 million by switching patients to the generic version.
Pharmacies and pharmacists can help the rapid deployment of COVID-19 vaccines when available, NACDS said.
The SIMPLE trial found the 5-day remdesivir treatment arm to be 65% more likely to have clinical improvement compared with standard of care alone in patients with moderate COVID-19.
IW-3718, an investigational adjunct therapy to proton pump inhibitors for refractory GERD, showed favorable results in reducing heartburn severity and other symptoms.
An analysis found that US patients with COVID-19 are experiencing longer hospital stays and higher rates of ICU admissions than patients in China.
Can coronavirus-related stress cause shingles?